Ocular Therapeutix, Inc. Begins Phase 3 Clinical Trial For Its Sustained Release Dexamethasone
3/17/2014 9:18:38 AM
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix’s dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Help employers find you! Check out all the jobs and post your resume.
comments powered by